Indoco Remedies Ltd Stock Price Today (NSE: INDOCO)
Fundamental Score
Indoco Remedies Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Indoco Remedies Ltd share price today is ₹164.00, down 6.69% on NSE/BSE as of 30 March 2026. Indoco Remedies Ltd (INDOCO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.39K (Cr). The 52-week high for INDOCO share price is ₹349.80 and the 52-week low is ₹172.10. The company has a Return on Equity (ROE) of -7.02% and a debt-to-equity ratio of 1.02.
Indoco Remedies Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Indoco Remedies Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Indoco Remedies Share Price: A Financial Stability Analysis
The Indian pharmaceutical sector, while generally robust, often sees companies with niche specializations facing unique financial pressures. This analysis examines the financial stability of Indoco Remedies Ltd, particularly focusing on the recent performance of its stock. The current Indoco Remedies share price sits at ₹212.759995. A critical element to consider is the company's Price-to-Earnings (PE) ratio, which is currently unavailable, and its Return on Capital Employed (ROCE). This analysis is part of a larger, 80-parameter fundamental audit verified by Sweta Mishra.
One of the primary concerns highlighted in this evaluation is the company's ROCE of -0.49%. This negative ROCE suggests that the company is currently destroying value rather than generating profits from its capital investments. A consistently low or negative ROCE can significantly impact a company’s ability to build and maintain an economic moat. A strong moat protects a company from competitors; without it, Indoco Remedies Ltd may struggle to maintain market share and profitability in the long run. This contrasts starkly with sector leaders who possess strong moats built on innovation, brand recognition, or cost advantages.
Furthermore, comparing Indoco Remedies Ltd to its peers provides valuable context. For instance,
Mankind Pharma Ltd showcases a different approach to management quality, often reflected in its operational efficiencies and strategic decision-making. While specific details are unavailable without further analysis, examining management's history, capital allocation decisions, and responsiveness to market changes is crucial. Such comparisons can reveal areas where Indoco Remedies Ltd might improve its financial performance.The absence of a PE ratio, combined with the negative ROCE, warrants a deeper investigation into the underlying causes. Factors such as increased operating expenses, changes in revenue streams, or significant capital expenditures could contribute to this situation. Understanding these factors is crucial for assessing the long-term financial stability of Indoco Remedies Ltd. This assessment is based on publicly available data and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indoco Remedies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDOCO across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (21.91%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Balanced Promoter Holding (58.90%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-7.02%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.49%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Elevated Debt Levels (D/E: 1.02)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-0.50x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-498.58 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Indoco Remedies Ltd Financial Statements
Comprehensive financial data for Indoco Remedies Ltd including income statement, balance sheet and cash flow
About INDOCO (Indoco Remedies Ltd)
Indoco Remedies Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of finished pharmaceuti...cal dosages. With a strong emphasis on innovation and quality, Indoco has built a reputation for delivering effective and affordable healthcare solutions across diverse therapeutic segments. Their expansive product portfolio caters to both domestic and international markets, solidifying their position as a trusted partner in the global pharmaceutical landscape. Driven by a commitment to scientific excellence and ethical business practices, Indoco continuously strives to improve patient outcomes and contribute to the advancement of healthcare worldwide, all while maintaining rigorous adherence to international regulatory standards. The company's therapeutic focus is exceptionally broad, encompassing critical areas such as pain management, diabetes care, cardiovascular health, and women's health. Indoco's product offerings include a diverse range of formulations, including tablets, capsules, injectables, and topical preparations, each developed with a meticulous attention to detail and adherence to strict quality control measures. By leveraging cutting-edge technology and a highly skilled workforce, Indoco remains at the forefront of pharmaceutical innovation, constantly seeking to develop novel and improved therapies that address unmet medical needs. The company's strategic partnerships and collaborations further enhance its capabilities and expand its reach, ensuring that its products are accessible to patients across the globe. Indoco's commitment to sustainable growth is evident in its continuous investments in research and development, manufacturing infrastructure, and human capital. The company operates state-of-the-art manufacturing facilities that are compliant with international regulatory standards, ensuring the consistent production of high-quality pharmaceutical products. Furthermore, Indoco places a strong emphasis on environmental sustainability, implementing eco-friendly practices throughout its operations. By combining its dedication to scientific advancement with a responsible and ethical approach to business, Indoco Remedies Ltd is poised to continue its trajectory of growth and contribute meaningfully to the health and well-being of communities worldwide.
Company Details
Key Leadership
Corporate Events
INDOCO Share Price: Frequently Asked Questions
What is the current share price of Indoco Remedies Ltd (INDOCO)?
As of 30 Mar 2026, 12:07 pm IST, Indoco Remedies Ltd share price is ₹164.00. The INDOCO stock has a market capitalisation of ₹2.39K (Cr) on NSE/BSE.
Is INDOCO share price Overvalued or Undervalued?
INDOCO share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Indoco Remedies Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of INDOCO share price?
The 52-week high of INDOCO share price is ₹349.80 and the 52-week low is ₹172.10. These values are updated daily from NSE/BSE price data.
What factors affect the Indoco Remedies Ltd share price?
Key factors influencing INDOCO share price include quarterly earnings growth (Sales Growth: 12.02%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Indoco Remedies Ltd a good stock for long-term investment?
Indoco Remedies Ltd shows a 5-year Profit Growth of N/A% and an ROE of -7.02%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.02 before investing in INDOCO shares.
How does Indoco Remedies Ltd compare with its industry peers?
Indoco Remedies Ltd competes with major peers in the Pharmaceuticals. Investors should compare INDOCO share price P/E of 0.00x and ROE of -7.02% against the industry averages to determine competitive standing.
What is the P/E ratio of INDOCO and what does it mean?
INDOCO share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is INDOCO performing according to Bull Run's analysis?
INDOCO has a Bull Run fundamental score of 20.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INDOCO belong to?
INDOCO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Indoco Remedies Ltd share price.
What is Return on Equity (ROE) and why is it important for INDOCO?
INDOCO has an ROE of -7.02%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Indoco Remedies Ltd generates profits from shareholders capital.
How is INDOCO debt-to-equity ratio and what does it indicate?
INDOCO has a debt-to-equity ratio of 1.02, which indicates high leverage that increases financial risk.
What is INDOCO dividend yield and is it a good dividend stock?
INDOCO offers a dividend yield of 0.08%, meaning you receive ₹0.08 annual dividend for every ₹100 invested in Indoco Remedies Ltd shares.
How has INDOCO share price grown over the past 5 years?
INDOCO has achieved 5-year growth rates of: Sales Growth 8.51%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in INDOCO and why does it matter?
Promoters hold 58.90% of INDOCO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Indoco Remedies Ltd.
What is INDOCO market capitalisation category?
INDOCO has a market capitalisation of ₹2390 crores, placing it in the Small-cap category.
How volatile is INDOCO stock?
INDOCO has a beta of N/A. A beta > 1 suggests the Indoco Remedies Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INDOCO operating profit margin trend?
INDOCO has a 5-year average Operating Profit Margin (OPM) of 14.94%, indicating the company's operational efficiency.
How is INDOCO quarterly performance?
Recent quarterly performance shows Indoco Remedies Ltd YoY Sales Growth of 12.02% and YoY Profit Growth of 21.91%.
What is the institutional holding pattern in INDOCO?
INDOCO has FII holding of 1.25% and DII holding of 18.16%. Significant institutional holding often suggests professional confidence in the Indoco Remedies Ltd stock.